MetiMedi Pharmaceutical Co., Ltd.’s CID (Chronic Inflammatory Disease) patent was divided into three separate applications in the United States, and patent examinations are currently ongoing. On August 25, 2020, MetiMedi’s patents for multiple sclerosis, age-related macular degeneration, and non-alcoholic steatohepatitis (NASH) passed review by the U.S.

Patent Office and were successfully registered. Furthermore, on January 26, 2021, the U.S. Patent Office approved and registered MetiMedi’s patents for Alzheimer’s disease, Parkinson’s disease, atherosclerosis, and inflammatory bowel disease. MetiMedi is continuing efforts to secure additional patents for other chronic inflammatory diseases.